A silver sulphadiazine-impregnated lipidocolloid wound dressing to treat second-degree burns.
OBJECTIVE
To evaluate the efficacy and tolerance of Urgotul SSD dressing (Laboratoires Urgo) in the treatment of second-degree burns.


METHODS
This was a national multicentre phase III non-comparative open-label prospective study involving 10 burns units. The 41 subjects were non-immunosuppressed adults with second-degree thermal burn(s), which were clinically non-infected, less than 24 hours old, had a surface area less than 500 cm2 and warranted the local use of silver sulphadiazine. For four weeks, subjects were followed up weekly with a clinical assessment, bacteriological swabs and photographic recording.


RESULTS
Of the 41 patients, 24 healed within a mean of 10.8 days and 13 had a skin graft on the study burn within a mean of 11.5 days. There were four premature study withdrawals. The total number of cumulative treatment days was 445, and 298 treatments were performed (including 257 dressing changes). Mean dressing wear time was 1.73 days. None of the subjects acquired a secondary infection. Researchers took 121 bacteriological samples, and wound colonisation with Staphylococcus aureus was found in only one patient. At follow-up nursing staff reported that dressing acceptability was good.


CONCLUSIONS
Use of Urgotul SSD led to a good wound outcome--wounds healed or were grafted.
Carsin
H
H
Burn Unit, Hôpital Percy, Clamart, France. hcarsin@numericable.fr
Wassermann
D
D
Pannier
M
M
Dumas
R
R
Bohbot
S
S
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000891:Anti-Infective Agents, Local / Q000627:therapeutic use*; D002056:Burns / Q000150:complications / Q000188:drug therapy* / Q000451:nursing*; D003102:Colloids / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008055:Lipids / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009779:Occlusive Dressings; D012837:Silver Sulfadiazine / Q000627:therapeutic use*; D016896:Treatment Outcome; D014945:Wound Healing / Q000187:drug effects; D014946:Wound Infection / Q000188:drug therapy / Q000209:etiology / Q000517:prevention & control
D000891:Anti-Infective Agents, Local; D003102:Colloids; D008055:Lipids; D012837:Silver Sulfadiazine